Thalidomide-related adverse events
During 6 months follow-up, adverse events were reported in 48 (63.2%)
patients, including dizziness and/or lethargy (n=24), constipation(n=9),
abdominal pain and/or vomiting and/or nausea (n=9), arthralgia (n=4),
edema (n=3), peripheral neuropathy (numbness of extremities) and/or
headache(n=2), skin rash (n=1),leukocytopenia (n=7), neutrophil (n=10),
thrombocytosis (n=9). Two patients stopped using thalidomide due to
adverse events, including central venous thrombosis (n=1) and seizure
(n=1). Most the symptoms relieved spontaneously without withdraw, while
some symptoms relieved with temporary reduced dosage.